Our previous studies demonstrated that patients with HBV-HCC have higher serum IL-6 concentrations, where IL-6 promotes CSC-associated properties by activating the IGF-1/IGF-1R signaling pathway.7 The gene discussed is IGF1; the disease is hepatocellular carcinoma.